Geographic Segments

9 Months Ended

Mar. 31, 2018

10.Geographic Segments

Immunomedics manages its operations as one line of business of researching, developing, manufacturing and marketing biopharmaceutical products, particularly antibody-based products for cancer and other serious diseases, and it currently reports as a single industry segment. Immunomedics conducts its research and development activities primarily in the United States. Immunomedics marketed and sold LeukoScan® throughout Europe and in certain other countries outside the United States through February 2018; at which the Company discontinued these sales.

The following table presents financial information based on the geographic location of the facilities of Immunomedics as of and for the three and nine-months ended March 31, 2018 and 2017, respectively ($ in thousands):





	As of March 31, 2018		As of June 30, 2017
Total assets:
United States	$	377,791	$	161,484
Europe		2,097		1,089
Total	$	379,888	$	162,573





	As of March 31, 2018		As of June 30, 2017
Property and equipment, net:
United States	$	10,590	$	5,166
Europe		79		79
Total	$	10,669	$	5,245


	For the three months ended
	March 31, 2018
	2018		2017
Revenues:
United States	$	32	$	401
Europe		450		922
Total	$	482	$	1,323

(Loss) income before taxes:
United States	$	(35,600)	$	(59,378)
Europe		42		58
Total	$	(35,558)	$	(59,320)


	For the nine months ended
	March 31, 2017
	2018		2017
Revenues:
United States	$	269	$	613
Europe		1,501		1,836
Total	$	1,770	$	2,449

(Loss) income before taxes:
United States	$	(156,937)	$	(99,812)
Europe		89		(185)
Total	$	(156,848)	$	(99,997)